As a pharmaceuticals executive with nearly three decades of
experience, Ellen Scharaga maintains a close relationship with the healthcare
industry. Currently involved in the upper management of a group that deals
specifically in oncology, she holds an even deeper perspective on the effects
of cancer. Committed to research into the epidemic, Ms. Scharaga donates to the Leukemia
& Lymphoma Society.
Established in 1949, the Leukemia & Lymphoma Society
aims to change the way we deal with these types of cancers, from the treatments
available to patients to the resources available to their families. Since
establishment, the organization poured more than $750 million into research
concerning blood cancers and significantly increased the lifespan of
individuals affected by these conditions. The group oversees nearly 70 chapters
throughout the United States and the doctors at the head of studies regularly
receive awards including the Nobel Prize and the Albert Lasker Clinical Medical
Research Award. Treatment and research innovations spearheaded by the
organization include the first successful bone marrow transplant, the
identification of drug combinations that lead to long-term remissions in
children, the use of organic cell products to improve immune system
performance, and the architecture of revolutionary targeted therapies. In
recent years, the Leukemia & Lymphoma Society worked to release a number of
groundbreaking drugs, among them Velcade, Rituxan, and Gleevac.
In order to continue the life-saving research made possible
by the Leukemia & Lymphoma Society, volunteers gather at numerous
fundraising events including Light the Night Walk, Team Training, and American
Bicycle Race for Life. To learn more about the group’s progress or how to
contribute, visit lls.org.
Posts
No comments:
Post a Comment